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Abstract  
Fas, also known as CD95 or APO-1, is a member of the tumour necrosis factor/nerve growth 
factor (TNF/NGF) superfamily. Although best characterised in terms of its apoptotic 
function, recent studies have identified several other cellular responses emanating from Fas. 
These responses include migration, invasion, inflammation and proliferation. In this review 
we focus on the diverse cellular outcomes of Fas signalling and the molecular switches 
identified to date that regulate its pro- and anti-apoptotic functions. Such switches occur at 
different levels of signal transduction, ranging from the receptor through to cross-talk with 
other signalling pathways. Factors identified to date including other extracellular signals, 
proteins recruited to the DISC and the availability of different intracellular components of 
signal transduction pathways. The success of therapeutically targeting Fas will require a 
better understanding of these pathways, as well as the regulatory mechanisms that determine 
cellular outcome following receptor activation.  
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Introduction 
Fas (CD95/APO-1) is a member of the tumour necrosis factor/nerve growth factor 
(TNF/NGF) superfamily [1,2]. Members of this family function in cellular differentiation, 
proliferation and activation. Following the discovery that mutations in Fas and Fas ligand 
(FasL/CD95L) were the underlying cause of the massive lymphadenopathy and autoimmune 
lymphoproliferative syndrome in lpr and gld mice, respectively, subsequent studies on the 
Fas system focused primarily on its role in apoptosis. Recent studies suggest however, that 
other cellular responses may emanate from Fas. Signalling through Fas has been shown to 
activate the three main mitogen-activated protein kinase (MAPK) pathways, p38, JNK1/2 and 
ERK1/2, as well as the transcription factor NFB, leading to cell proliferation, migration and 
inflammation. However, the molecular mechanisms leading to activation of such pathways 
and hence the physiological outcome of Fas signalling are not fully understood. This review 
aims to outline what is known about these roles of Fas and the factors that regulate cell fate 
following Fas ligation. 
 
Fas and FasL 
Fas is a prototypical death receptor consisting of a N-terminal region containing three 
cysteine-rich domains (CRDs), with ligand binding occurring predominantly at the 2
nd
 and 3
rd
 
CRDs, a transmembrane domain and an intracellular region containing an ~ 80 amino acid 
domain called the ‘death domain’ (DD) [3]. This DD is essential for transduction of the 
apoptotic signal. Fas is predominantly located at the cell surface, where it has been shown to 
pre-associate in homotrimers [4]. It is ubiquitously expressed in the body, but is particularly 
abundant in liver, heart, brain and colon tissues, and in activated mature lymphocytes [5-7].  
In contrast to its receptor, Fas ligand has a much more restricted pattern of expression, 
being found mainly in haematopoietic cells and in immune privileged sites such as the eye 
and testis. FasL was originally discovered on cells of the lymphoid/myeloid lineage, 
including activated T cells and natural killer cells [8]. In the immune system, the FasL/Fas 
system plays an important role in the down-regulation of immune reactions, being involved in 
activation-induced cell death (AICD), a process whereby activated T cells are eliminated at 
the end of an immune response, as well as T cell and natural killer cell-mediated cytotoxicity 
[9]. In immune privileged sites, constitutively expressed FasL triggers apoptosis of activated 
inflammatory cells entering the sites, helping to protect these sites from a potentially 
disastrous inflammatory immune response [10].  
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Although synthesized as a transmembrane protein, FasL can be cleaved by 
metalloproteinases, releasing a soluble form (sFasL). The apoptotic activity of sFasL is far 
less than that of the membrane-bound form [11], and it appears in some instances to be a 
mechanism for downregulating at least part of its apoptotic activity [12]. Membrane-bound 
FasL can also be internalised and trafficked to secretory lysosomes. FasL secreted in these 
microvesicles is regarded as being biologically active [13,14]. Similar to Fas, FasL can also 
self-associate into a homotrimer, with binding of FasL homo-trimers to the pre-associated Fas 
inducing the formation of receptor micro-aggregates [15].  
 
Fas-mediated apoptosis 
Upon ligation by FasL, Fas receptors multimerize in the cell membrane which leads to 
a conformational change in the intracellular domain of the receptor [16].  This in turn leads to 
the recruitment of the DD-containing adaptor molecule Fas-associated death domain (FADD) 
through DD-DD interactions, with FADD in turn recruiting the initiator caspase, pro-caspase-
8, forming a signalling complex called the death-inducing signalling complex (DISC). 
Formation of the DISC occurs within seconds after Fas ligation [17,18]. At the DISC, 
oligomerization of pro-caspase-8 occurs, facilitating its autoactivation through self-cleavage, 
followed by the release of active proteases [19]. Depending on which signalling pathway is 
activated following ligation of Fas, apoptosis proceeds through one of two pathways, either 
the extrinsic or intrinsic apoptosis pathway, with cells classified as either type I or type II 
[18,20]. In the extrinsic apoptosis pathway, following effective formation of the DISC, 
activated caspase-8 directly activates downstream effector caspases such as caspase-3, -6 and 
-7, resulting in the cleavage of a restricted set of target proteins and culminating in the 
apoptotic death of the cell (type I cells). Efficient formation of the DISC and caspase-8 
activation was shown to require receptor internalisation, as blocking Fas internalization 
impaired DISC formation and apoptosis [21]. Indeed recruitment of FADD and pro-caspase-8 
to the activated receptor occurred predominantly after the receptor had moved into an 
endosomal compartment [21]. 
In contrast, in type II cells, DISC formation and caspase-8 activation is reduced, and 
in these cells the mitochondria serve an essential role as signal amplifiers. This mitochondrial 
or intrinsic apoptotic pathway is activated by cleavage of the BH3-only pro-apoptotic protein 
Bid by caspase-8. Truncated Bid translocates to the mitochondria where, through its effects 
on members of the Bcl-2 family, it induces the release of pro-apoptotic molecules including 
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cytochrome c and second mitochondria-derived activator of caspase (SMAC). Caspase-9 is 
then activated upon association with cytochrome c and the apoptotic protease-activating 
factor 1 (Apaf-1) in a multiprotein complex known as the apoptosome. Activated caspase-9 
activates the effector caspases, ultimately resulting in the apoptotic death of the cell.  
Fas-mediated apoptosis in many cells has been shown to involve the redistribution 
and clustering of Fas in lipid rafts [22], followed by recruitment of the DISC components to 
these rafts [23-25]. This redistribution and clustering of Fas in lipid rafts can also be 
pharmacologically mediated, and is sufficient to mediate the activation of the apoptotic signal 
independent of the presence of FasL [22,23,26]. Indeed, re-distribution of  Fas into lipid rafts 
has recently been shown to promote the conversion of cells from a type II to a type I-like 
phenotype [27].  
Regulation of the level of X chromosome-linked inhibitor of apoptosis protein (XIAP) 
has also been recently shown to dictate whether a cell undergoes type I or type II Fas-
mediated apoptosis [28]. XIAP is a potent inhibitor of caspase-3, -7 and -9 [28], and is itself 
inhibited by SMAC released by the mitochondria. Fas stimulation led to a reduction in the 
level of XIAP in type I cells, but an increase in XIAP in type II cells. Moreover, genetic 
ablation of XIAP in type II cells changed their phenotype to that of type I cells [28]. 
However, the mechanism responsible for this differential regulation of XIAP levels in 
response to Fas activation in type I and type II cells remains unclear.   
 
Fas-induced proliferation 
One of the first indications that the Fas system may have additional, non-apoptotic, 
functions came from studies showing that ligation of Fas augmented proliferation of CD3-
activated primary T cells [29]. Sensitivity of human T cells to Fas-mediated apoptosis 
depends on their activation status. Naive T cells are resistant, with sensitivity to Fas-induced 
cell death developing 6–7 days after T cell activation [30], consistent with the important role 
of FasL/Fas in AICD. An unexpected finding, however, was that ligation of Fas could co-
stimulate the proliferation of these naive T cells [29]. Further investigations suggested that 
the physiological response of T cells to Fas ligation is determined by the antigenic history of 
the cell and the availability of co-stimulation [31]. Activation of T cells requires two main 
signals; engagement of the TCR/CD3 complex (signal 1), together with a second co-
stimulatory signal (signal 2), usually provided by the ligation of ‘classical’ co-stimulatory 
receptors including CD28. In the absence of exogenous rescue signals such as CD28 co-
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stimulation or TH1 (IL-12) and TH2 (IL-4) differentiation cytokines, the default response of 
TCR/CD3-stimulated naive CD4
+
 T cells to Fas activation was apoptosis. In contrast, despite 
the absence of exogenous rescue signals, TCR/CD3-stimulated memory T cells proliferated 
more rapidly as a consequence of Fas ligation [31].  
The outcome of Fas ligation was also proposed to depend on the strength or ‘dose’ of 
the anti-Fas agonist [32]. High concentrations of Fas agonists inhibited the proliferation of 
primary human naive CD4
+
 T cells, while low doses of the very same Fas agonists promoted 
TCR-triggered NFB and MAPK activation and enhanced T cell proliferation compared to 
conventional co-stimulation through the classical co-stimulatory CD28 molecule [32,33]. 
Such a low concentration of FasL is found on antigen-presenting cells (APC) at the onset of 
an immune response [34].Together these findings suggest that the FasL/Fas system may, in a 
cell context-specific manner, replace the conventional co-stimulatory signal required by naive 
T cells for proliferation (signal 2). Thus, in addition to its role in the contraction phase of an 
immune response (AICD), Fas/FasL may support T cell expansion at the onset of an immune 
response, as well as contributing to the increased efficiency and accelerated kinetics 
displayed during memory responses.   
T cells are not the only cell type in which this classically pro-apoptotic molecule has 
been shown to modulate cell growth, with a variety of non-immunological cells including B 
cells, fibroblasts and tumour cells also shown to respond to Fas stimulation with enhanced 
proliferation [35-39]. For instance, reducing Fas or FasL expression in a variety of tumour 
cell lines was recently shown to reduce cell proliferation in vitro, with optimal tumour growth 
depending on constitutive signalling through Fas by FasL in vivo [38]. Enhanced tumour 
growth was proposed to be due to FasL-mediated activation of JNK and ERK, resulting in 
phosphorylation of Jun and increased expression of the Egr1 and Fos transcription factors 
[37,38] (Fig. 1). Activation of Fas was also shown to promote liver regeneration following 
partial hepatectomy in mice [39]. This contrasts sharply with the massive hepatocyte 
apoptosis that occurs in mice following intraperitoneal injection of Fas-activating antibodies 
[40]. Ligation of Fas by FasL also induced proliferation in quiescent hepatic stellate cells, 
with the mitogenic signal shown to be due to FasL-induced phosphorylation of the epidermal 
growth factor receptor (EGFR), and subsequent ERK activation. At the same time, cell death 
was prevented by FasL-mediated inactivation of the Fas receptor by tyrosine nitration [41].  
Multiple functions of Fas have also been described in neuronal cells. In addition to the 
induction of neuronal cell apoptosis, several studies have suggested that Fas may play a role 
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in regulating neuronal development, growth, differentiation and regeneration in the central 
nervous system [42]. Both Fas and FasL are widely expressed in the nervous system [43,44]. 
Instead of inducing neuronal apoptosis, ligation of Fas triggered neurite outgrowth and 
branching [7,45], and accelerated nerve regeneration following sciatic nerve injury in vivo 
[7]. In a model of traumatic brain injury, activation of Fas was initially detrimental, inducing 
apoptosis, but later in the course of the disease, was beneficial, promoting regeneration by 
mediating neuronal branching [46]. Fas-induced neurite growth was shown to require 
recruitment of ezrin, a molecule that links transmembrane proteins to the cytoskeleton, to Fas 
and subsequent activation of the small GTPase Rac1 [47]. FasL-mediated activation of ERK 
further promoted process elongation and branching, fine-tuning process morphology [7,47].  
Additional evidence supporting a role for non-apoptotic Fas signalling in the nervous 
system under certain circumstances comes from lpr mice. Fas-deficient lpr mice develop 
autoimmune disease due to an accumulation of immature and mature T cells as a result of 
impaired Fas-mediated immune homeostasis.  These mice also exhibit a variety of 
neurological defects, with such defects mostly attributed to this auto-immune disease [48]. 
However, despite the ability of potent immunosuppressive drugs to prevent the development 
of autoimmune disease in the lpr mouse, they had no effect on the neurological defects seen 
in these mice [42], suggesting that the neurological degeneration may be due to a lack of Fas-
mediated proliferation and survival signals.  
 
Fas-mediated suppression of T cell activation 
In addition to the roles outlined thus far for FasL/Fas, a third function has been 
attributed to the FasL/Fas system specific to T cells – suppression of T cell activation (Fig. 
2). Activation of T cells through the TCR triggers the recruitment of a series of tyrosine 
kinases and substrates to the TCR/CD3 complex, ultimately triggering the release of calcium 
(Ca
2+
) from the endoplasmic reticulum stores into the cytoplasm. Emptying of these stores 
triggers an influx of extracellular Ca
2+
 through the opening of Ca
2+
 release-activated Ca
2+
 
channels (CRAC) in the plasma membrane, resulting in sustained Ca
2+
 influx [49]. This 
elevation of intracellular free Ca
2+
 is one of the key triggering signals for T cell activation by 
antigen, resulting in the activation of the transcription factor NFAT and the subsequent 
production of IL-2. Cross-linking of Fas on T cells prior to stimulation with anti-CD3 mAb 
almost completely inhibited TCR-mediated Ca
2+
 influx [50]. This suggests that Fas-mediated 
inhibition of Ca
2+
 influx through CRAC channels could prevent T cell activation due to 
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impaired transcription factor activation and IL-2 synthesis, perhaps resulting in the induction 
of T cell anergy.  
Further investigations revealed that the inhibition of TCR-mediated Ca
2+
 influx was 
mediated by acidic sphingomyelinase (aSMase) (Fig. 2) [51]. Crosslinking of Fas resulted in 
the activation of aSMase, which hydrolyses sphingomyelin, a ubiquitous membrane 
sphingolipid, to generate phosphocholine and ceramide [52]. Ceramide, or its metabolite 
sphingosine, was found to block Ca
2+
 influx through the CRAC channels in lymphocytes, 
impairing NFAT activation and IL-2 synthesis [51,53]. Thus, the upregulation of FasL that 
occurs during an immune response may, in addition to the induction of apoptosis of activated 
cells, further aid in the contraction phase of the immune response by preventing the activation 
of resting cells. Indeed, numerous viruses induce FasL expression in APC, with such APCs 
impaired in their ability to activate T cells [53], suggesting that this may represent a potential 
mechanism of viral immune evasion.  
Together, these differing effects of Fas on T cells i.e. AICD, co-stimulation and 
suppression of T cell activation may play an important role in regulating the immune 
response, ensuring optimal T cell activation during the initial activation and expansion phase, 
whilst also being important for the termination of the immune response. For instance, FasL 
co-stimulation was shown to be necessary for maximal proliferation of cytotoxic T cells 
(CTL) in vivo [54]. Also, in an induced model of lupus, Fas on CD4
+
 T cells was shown to be 
important in providing help for CD8
+
 T cells, while Fas on CD8
+
 T cells was shown to be 
important  in effector downregulation [55]. Moreover, CD4
+
 T cells and CD8
+
 T cells appear 
to exhibit different sensitivities to Fas-mediated apoptosis, with CD8
+
 T cells more sensitive 
than CD4
+
 T cells [56]. 
 
 
Induction of cell migration and invasion by Fas  
Numerous studies have shown that signalling through Fas can promote cell migration 
and invasion, in particular in apoptosis-resistant malignant cells [57-59]. For instance, in 
pancreatic cancer cells TNF receptor associated factor 2 (TRAF2) was shown to not only 
protect cells from Fas-mediated apoptosis but also to strongly enhance Fas-mediated cell 
invasion [59]. Moreover, TRAF2 was recently shown to promote proteasomal degradation of 
active caspase-8, raising the signalling threshold for death receptor-induced apoptosis [60]. 
TRAF2 mediates signal transduction from members of the TNF receptor superfamily and is 
required for both TNFα and Fas- mediated activation of NFB and JNK. NFB can be 
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activated in cells via two main activating pathways [61]. The specific pathway linking Fas to 
NFB is unclear, with studies implicating both the canonical [62,63] and non-canonical 
[64,65] NFB activation pathways as being important for Fas-induced NFB activation. The 
reasons for these opposing findings are unclear, but may be due to differences in the cell type 
analysed.  
Activation of Fas in TRAF2 over-expressing cells resulted in enhanced activation of 
NFB and AP-1, increased secretion of extracellular matrix-degrading metalloproteinases 
(MMPs), urokinase-type plasminogen activator (uPA) and IL-8, and subsequently increased 
invasion. Moreover, induction of cellular migration by Fas in both breast and ovarian cancer 
cells was shown to be far greater than that seen with other members of the TNF family, 
including TRAIL and TNFα, and required activation of NFB, ERK1/2 and caspase-8 [57] 
(Fig. 3).  
Several recent studies have further characterised the signalling pathways activated by 
Fas that mediate Fas-induced migration and invasion. Activated Fas was shown to recruit 
both the Src family kinase Yes and the p85 subunit of PI3 kinase (PI3K) in glioblastoma 
cells, leading to PI3K activation and the expression of MMPs such as MMP2 and MMP9 
[66]. FasL also activated PI3K in macrophages and neutrophils, in this case via recruitment 
and activation of Syk kinase, leading to activation of MMP-9, and ultimately increased 
migration of the cells [67]. This increased secretion of MMPs is thought to play an important 
role in Fas-mediated invasion, facilitating cell migration through the extracellular matrix 
[68]. 
The formation of actin-driven cell protrusions are also thought to be required for Fas-
induced invasion [68]. In colorectal cancer cells, activation of Fas by FasL induced the 
formation of actin-driven cell protrusions through Rac and the cofilin pathway [69]. 
Activated Fas promoted the phosphorylation of platelet-derived growth factor receptor-β 
(PDGF- β) by an unknown mechanism, leading to phosphorylation of phospolipase C 1. 
This in turn ultimately resulted in the liberation of the actin-severing protein cofilin from the 
plasma membrane, initiating cortical actin remodelling and the formation of membrane 
protrusions [69]. Fas-activated Rac plays an important role in this process [47], with 
concomitant activation of the cofilin pathway and Rac driving the formation of cell 
protrusions required for migration and invasion [68] (Fig. 3).     
Another protein recently shown to play a role in Fas-induced invasion is TRIP6 [70]. 
TRIP6 is a focal adhesion molecule that serves as a platform for the recruitment of a number 
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of molecules involved in actin assembly, cell motility and survival. Interestingly, TRIP6 was 
recently shown to antagonise binding of FADD to Fas, inhibiting apoptosis, whilst at the 
same time promoting activation of NFB and cell migration [70] (Fig. 3).  
In addition to normal physiological roles such as neurite outgrowth, Fas-mediated 
migration and invasion may also play an important role in tumour recurrence following 
treatment of colorectal liver metastases. Signalling through Fas by FasL was shown to play 
an important role in local tumour cell invasion and accelerated outgrowth of micrometastases 
following both radiofrequency ablation [71] and ischemia/reperfusion injury which can occur 
during partial liver resection [72]. Both of these treatments are used to treat individuals with 
colon cancer that has metastasized to the liver, suggesting that targeting Fas-induced 
migration and invasion may be of therapeutic benefit.   
 
Fas as an activator of inflammation 
Some of the first evidence that FasL/Fas signalling could trigger inflammation came 
from allograft studies of FasL over-expressing tissues and tumours [73,74]. In these studies, 
ectopic over-expression of FasL resulted in extensive neutrophil recruitment and graft 
rejection in many cases. Numerous studies have since demonstrated that activation of Fas 
signalling in a variety of non-lymphoid cells including colonic and lung epithelial cells  [75-
77], hepatocytes [78], synoviocytes [79], macrophages [80,81] and fibroblasts [82,83] can 
lead to the expression and release of inflammatory factors in vitro and in vivo. Such factors 
may in turn recruit inflammatory cells, exacerbating the inflammatory process. Accordingly, 
Fas/FasL-mediated inflammation has been implicated in playing an important role in the 
pathogenesis of several diseases, including acute respiratory distress syndrome [77], cystic 
fibrosis [84], arthritis [79,85] and cancer [86], all of which have an underlying inflammatory 
component. Moreover, many chronic inflammatory diseases are attenuated in mice lacking 
Fas or FasL [85,87,88].  
Cytokines and chemokines induced by Fas include interleukin-6 (IL-6), IL-8, IL-1β, 
TNFα, MCP-1 (monocyte chemoattractant protein-1), IP-10 (interferon-gamma-induced 
protein 10) and prostaglandin E2 (PGE2). IL-6, IL-1β and PGE2 are multi-functional pro-
inflammatory cytokines. IL-8 is a neutrophil chemoattractant while MCP-1 and IP-10 are 
chemotactic for monocytes and T cells, respectively. Fas-induced cytokine production 
predominantly involves the activation of NFB and the p38, JNK and ERK MAPK signalling 
pathways [76,79] (Fig. 4). Several recent studies, however, have shown that MyD88 may also 
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play a role in this process. MyD88 is an adaptor molecule more commonly associated with 
inflammatory cytokine production by the Toll-like receptor (TLR) family of pattern 
recognition receptors and the interleukin-1 receptor (IL-1R) family. Similar to FADD, 
MyD88 also has a DD, allowing the potential binding of MyD88 to Fas via DD-DD 
interactions. Fas-induced KC (murine analog of IL-8) production by alveolar epithelial cells 
was shown to be dependent on MyD88 (Fig. 4) [77], while Fas-induced chemokine 
production by macrophages was also shown to be reduced in cells lacking MyD88 [89]. 
FADD-deficient cells also displayed enhanced TLR4- and TLR2-induced pro-inflammatory 
protein production [90]. This was proposed to be due to the interaction of FADD with 
MyD88 and IRAK1 (a TLR signalling molecule), with FADD reducing the stability of the 
MyD88-IRAK1 interaction, thereby attenuating the TLR4-induced signal [90]. 
Further evidence of cross-talk between the TLR, IL-1R and FasL/Fas pathways comes 
from studies showing that TLR4 and IL-1R1 signalling is reduced in lpr peritoneal 
macrophages and that blocking FasL/Fas interactions in macrophages suppresses LPS-
induced (TLR4 agonist) and IL-1R1-induced inflammatory cytokine production [85]. LPS- 
activated macrophages also produce a large amount of IL-1 upon FasL stimulation [91], 
suggesting that TLR-mediated induction of cytokines and chemokines may in part be due to 
enhanced Fas-induced inflammatory cytokine/chemokine production. Consistent with this, 
Fas-deficient mice are resistant to LPS-induced lethality after P. acnes treatment [92], while 
TLR4 signalling is reduced in lpr/lpr and gld/gld peritoneal macrophages [85]. Moreover, 
interruption of Fas/FasL interaction suppressed LPS-induced macrophage production of IL-6 
and TNF [85]. Alternatively, signalling through Fas may regulate TLR-induced 
inflammation due to cross-talk between the signalling pathways downstream of the receptors. 
In the absence of Fas ligation, the Fas adaptor molecule, FADD was shown to interact with 
the TLR adaptor MyD88 in the cytoplasm, potentially blocking/limiting MyD88 signalling 
(Fig. 4) [85]. Further studies are required to elucidate the extent of the cross-talk between 
these pathways and to determine how important this cross-talk is in promoting Fas-induced 
inflammation. 
 
Reverse signalling through FasL 
Although predominantly described in terms of its ability to activate signalling through 
Fas, several studies have shown that FasL may also transduce a signal into the cell. This 
phenomenon of reverse or retrograde signalling has primarily been described in T cells, and 
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in this situation Fas acts as the ligand for membrane-bound FasL, transmitting a signal into 
the FasL-expressing cell. This reverse signal has been shown to be due to the recruitment of 
Src homology 3 (SH3) domain-containing proteins such as Fyn, Grb2 and the p85 subunit of 
PI3K to the cytoplasmic region of FasL [93,94] (Fig. 5). One of the first reports of reverse 
signalling in non-T cells was in cancer cells, with reverse signalling through FasL enhancing 
cell migration [95]. This enhanced migration was due to interaction of FasL with, and 
subsequent activation of, the hepatocyte growth factor receptor Met. FasL was shown to 
complex with Met and activate the Met signalling pathway in tumour cells, promoting tumour 
cell migration and metastasis [95]. Moreover, reverse signalling through FasL has also 
recently been shown to occur in the nervous system [96]. Stimulation of FasL on Schwann 
cells induced the secretion of nerve growth factor (NGF), with NGF secretion requiring the 
activation of the Src and the MAPK ERK1/2 pathways. NGF, in turn, stimulating neurite 
outgrowth in vitro [96]. Further work, however, is required to fully elucidate the 
physiological role of reverse signalling through FasL in vivo.  
 
Regulation of the outcome of Fas signalling 
What regulates the outcome of Fas signalling, and why Fas stimulation in some cells 
results in apoptosis, whilst in other cells a variety of non-apoptotic signalling pathways are 
activated, remains unclear. Several mechanisms have been proposed, with the final outcome 
potentially a combination of some or all of these mechanisms. 
 
Soluble versus membrane-bound FasL:  
The outcome of Fas signalling may potentially be determined by the form of the 
ligand that activates the receptor (Fig. 6a). Cleavage of membrane-bound FasL (mFasL) from 
the cell surface generates soluble FasL (sFasL). These forms of FasL differ greatly in their 
apoptotic activity, with sFasL being far less apoptotic than mFasL [12,97]. Indeed, cleavage 
of mFasL to sFasL may represent a potential mechanism to downregulate the activity of 
mFasL [12,97,98].  Thus, depending on the form of FasL that binds to Fas, different 
signalling pathways may be activated.  
Consistent with this, in a mouse model of glaucoma, full length mFasL was shown to 
play a major role in retinal neurotoxicity, with administration of sFasL protecting against the 
death of the retinal ganglion cells [99]. Using lymphoma cells transfected with the different 
forms of FasL, Hohlbaum et al showed that sFasL not only blocked the apoptotic activity of 
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mFasL but also opposed the pro-inflammatory activity of mFasL in vivo [100]. mFasL also 
triggered the production of pro-inflammatory cytokines by monocytes and macrophages 
[81,101], with cardiac-specific expression of sFasL inhibiting activation of macrophages and 
pro-inflammatory cytokine production in a model of heart disease [102].   
In addition to its role in down-regulating the activity of mFasL, sFasL may also 
potentially activate non-apoptotic signalling pathways. In a recent study using gene-targeted 
mice engineered to lack either sFasL or mFasL, mFasL was found  to be essential for Fas-
induced killing of target cells by T cells and for activation-induced cell death [103]. 
However, in contrast to the previous studies demonstrating that sFasL inhibited mFasL-
mediated apoptosis and inflammation, in this study sFasL was proposed to be the form of 
FasL responsible for the pro-inflammatory function of FasL. Mice expressing sFasL alone 
contained abnormally elevated serum levels of pro-inflammatory cytokines including IL-6 
and TNFα and developed a fatal auto-immune disease and hepatic tumours [103], consistent 
with the ability of sFasL to activate NFB [103,104]. Moreover, in a mouse model of stroke, 
gld mice were found to have significantly improved neurological deficit scores [105]. Gld 
mice have a point mutation in the FasL gene that inactivates FasL function [106]. These mice 
had attenuated pro-inflammatory cytokine and chemokine production following cerebral 
ischemia. sFasL and JNK phosphorylation was decreased in gld mice, while in the ischemic 
cortex of the control B6 mice, the level of sFasL was greatly increased, suggesting that the 
reduction and dysfunction of sFasL in gld mice might contribute to the reduced inflammation 
seen in these mice, with sFasL potentially responsible for the FasL-induced inflammation 
seen [105]. 
Differences in the levels of receptor-interacting protein 1 (RIP1) in the cells analysed 
may account for these contradictory findings, with a recent study showing that RIP1 may 
play a role in modulating the differential outcome of signalling through sFasL and mFasL 
(Fig. 6d) [107]. RIP1 was shown to be required for the efficient activation of downstream 
caspases by Fas following stimulation with mFasL. Cross-linking sFasL bypassed the 
requirement for RIP1 by initiating the formation of larger, but less efficient DISC complexes 
than mFasL. It was proposed that when sFasL is associated with matrix proteins, such as may 
occur under physiological conditions, cell death does not occur due to the recruitment of less 
RIP1 to the DISC, thus favouring the activation of non-apoptotic signalling pathways [107].  
For a variety of reasons, many studies fail to distinguish between mFasL and sFasL, 
or investigate the function of FasL using soluble FasL corresponding to the entire 
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extracellular domain rather than the natural cleavage product [38,63,108]. Moreover, FasL 
can be released from cells by at least two mechanisms. In addition to metalloproteinase-
mediated cleavage of FasL from the cell surface to yield a truncated soluble product (sFasL), 
cell lines and activated T cells have been reported to release full-length FasL in the form of 
microvesicles [109,110]. ELISA assays don’t distinguish between sFasL and full-length FasL 
in microvesicles, possibly confounding the findings regarding the predominant function of 
sFasL and mFasL, and making it difficult to determine whether non-apoptotic Fas signalling 
is predominantly induced by sFasL and/or mFasL. Finally many cells express both sFasL and 
mFasL, and the predominant activity may thus be determined by the relative expression of 
the different forms.  
 
Regulation at the level of the receptor:  
The response to engagement of the Fas receptor by FasL in some cells appears to be 
determined at the level of the receptor (Fig. 6b), with studies showing that changes in 
receptor internalisation may play an important role in determining cell fate following Fas 
ligation [111]. Clathrin-mediated internalisation of Fas into endosomal compartments was 
shown to be required for optimum DISC formation and apoptosis to occur, with inhibition of 
internalisation resulting in Fas-induced activation of the NFB and ERK signalling pathways 
[21,112]. Binding of Fas initiates the rapid clustering of Fas in lipid rafts  which aggregate in 
large clusters that are internalised [113]. Post-translational palmitoylation of Fas was shown 
to be necessary for receptor localisation to lipid rafts, with mutations that prevented Fas 
palmitoylation resulting in a marked reduction in Fas translocation to lipid rafts, 
internalization and apoptosis [114]. Moreover, a conserved glycosphingolipid-binding motif 
located in the extracellular domain of Fas has been identified as being required for clathrin-
dependent Fas internalization, with loss of function switching Fas towards its non-apoptotic 
functions [112]. 
The strength of the activating signal may also play a role in the outcome of Fas 
ligation [115]. Although a large number of tumours have somatic mutations in the Fas death 
domain, they rarely display loss of heterozygosity, suggesting the presence of one wild-type 
allele confers an oncogenic advantage. Indeed, induction of apoptosis has been shown to 
require two wild-type alleles of Fas, whereas the signalling threshold to activate NFB is 
much lower, requiring the presence of just one wild-type allele [116]. Consistent with the 
strength of the activation signal playing an important role in determining cell fate, stimulation 
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of Fas in fibroblasts triggered proliferation in cells expressing low levels of the receptor, 
while those over-expressing the receptor died by apoptosis [36].  
Finally, sialylation of the Fas receptor by the golgi glycosyltransferase, ST6Gal-1, 
was recently shown to inhibit apoptotic signalling by Fas by decreasing the ability of FADD 
to bind to Fas, as well as inhibiting receptor internalisation [117]. ST6Gal-1 is upregulated by 
oncogenic K-Ras [118], with oncogenic K-ras recently implicated in playing a role in the 
switch in the cell response of colon cancer cells following Fas activation [119]. In the 
presence of oncogenic K-Ras, binding of FasL to Fas triggered cell migration and invasion, 
whereas deletion of the K-Ras effector, Raf1, was sufficient to switch the cell response back 
to apoptosis, abrogating the metastatic activity of the receptor [119].  
 
DISC-interacting proteins as determinants of cell fate: 
FLICE-like inhibitory proteins (c-FLIP) have been shown to play a role in modulating 
the outcome of Fas engagement (Fig. 6c). c-FLIP is a family of alternatively spliced variants, 
three isoforms of which are expressed as proteins and comprise: Long (c-FLIPL), Short (c-
FLIPS) and Raji (c-FLIPR). All three can bind to the DISC, with c-FLIPS and c-FLIPR 
blocking apoptosis by inhibiting the activation of pro-caspase-8 [120]. The role of c-FLIPL, 
however, in apoptosis is less clear [121]. In some cell contexts c-FLIPL has pro-apoptotic 
activity [122,123]. Ectopic expression of c-FLIPL at physiologically relevant levels was 
shown to enhance pro-caspase-8 processing in the DISC and promote apoptosis, while a 
decrease in c-FLIPL expression resulted in inhibition of apoptosis [123].  
Numerous other studies, however, have demonstrated an anti-apoptotic function for c-
FLIPL, with c-FLIPL linked to activation of NFB and the MAPK signalling pathways 
[79,124]. Inhibition of c-FLIP expression in rheumatoid synoviocytes resulted in a reduction 
in Fas-mediated NFB activation [79], while T cells over-expressing c-FLIPL were shown to 
exhibit increased proliferative responses following stimulation with sub-optimal doses of 
antigen [125]. Over-expression of c-FLIPL was shown to promote the activation of the NFB 
and Erk signalling pathways, together with the increased production of IL-2, via recruitment 
of adaptor proteins and kinases including TRAF-1, TRAF-2, RIP and Raf-1 to the DISC 
[126]. Similarly, in fibrotic lung myofibroblasts the switch from apoptosis to proliferation 
was shown to be mediated by c-FLIPL and required signalling through TRAF and NFB 
[127], while overexpression of TRAF2 in pancreatic cancer cells not only protected the cells 
from Fas-mediated apoptosis but also led to the constitutive activation of NFB and AP-1 
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[128]. Moreover the change in response of hepatocytes to Fas ligation (proliferation versus 
apoptosis) correlated with higher levels of FLIP in regenerating versus resting hepatocytes 
after treatment with anti-Fas [39].  
Finally, in several other studies FasL-induced NFB activity was shown to be 
inhibited by all c-FLIP variants. Knockdown of c-FLIP resulted in enhanced NFB activity, 
while over-expression of c-FLIP blocked Fas-induced NFB activation [129-131]. Over-
expression of c-FLIP suppressed Fas-induced RIP1 recruitment, a signalling protein that can 
interact with the IKK- (NEMO) subunit of the IB kinase (IKK) complex, and ultimately 
promote NFB activation [129].  
The reason for these conflicting reports on the role of c-FLIP in Fas-mediated 
signalling is unclear, but may be due to differences in the dose of FasL used. The same 
amount of c-FLIPL was shown to slow down cell death induction following weak Fas 
stimulation but to accelerate cell death upon stimulation with high doses of FasL [122]. 
Alternatively, differences in the concentrations of the c-FLIP isoforms in the different cell 
types analysed may account for the different results obtained in the different cellular systems. 
Recent systems biology approaches have shown that the stoichiometry of c-FLIP proteins and 
pro-caspase-8 in the DISC may be of critical importance in the outcome of receptor 
triggering, with the balance between the levels of c-FLIPL and pro-caspase-8 determining the 
outcome of Fas activation [63,122,132].  
Pro-caspase-8 has intrinsic catalytic activity, with this catalytic activity limited to pro-
caspase-8 itself and c-FLIP. In contrast, mature caspase-8 does not cleave pro-caspase-8, but 
instead efficiently cleaves effector pro-caspases, triggering the apoptotic signal [133]. At the 
DISC, heterodimer formation of pro-caspase-8 and c-FLIPL results in pro-caspase-8 
activation and in pro-caspase-8-mediated cleavage of c-FLIPL, generating p43-FLIP [63]. 
p43-FLIP, in turn can interact with TRAF2, ultimately leading to the activation of NFB 
[134]. However, both high and low concentrations of c-FLIPL inhibited p43-FLIP generation, 
and altering the ratio of pro-caspase-8 to c-FLIPL at the DISC was sufficient to alter the 
balance between apoptosis and NFB activation [63].  
In contrast to Fas-induced NFB activation [129,135], activation of the MAPK 
signalling pathways by Fas requires processing of pro-caspase-8 to caspase-8, with caspase-8 
activity shown to be necessary for activation of the MAPK pathways [129,132,136,137]. 
However, pro-caspase-8 is processed more rapidly in c-FLIPL-pro-caspase-8 heterodimers 
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than in pro-caspase-8 homodimers [122], with the ratio of c-FLIPL to caspase-8 at the DISC 
defining the amount of activated caspase-8 generated at the DISC. Thus, despite the 
requirement for pro-caspase-8 or caspase-8 activity by NFB [63] and MAPK [132], 
respectively for Fas-induced activation, the balance between c-FLIPL and pro-caspase-8 may 
regulate activation of both, suggesting that the composition of the Fas DISC may act as an 
important switch in determining whether apoptotic or non-apoptotic signalling prevails 
following Fas ligation.  
In addition to signalling through FADD and pro-caspase-8, recent studies suggest that 
Fas may recruit and signal through TRIP6 (Fig. 6d). Activation of Fas was shown to induce 
cytoskeletal reorganization, leading to the association of Fas with the adaptor proteinTRIP6 
[70]. In binding to Fas, TRIP6 interfered with FADD binding to the DD of Fas, thereby 
preventing apoptosis. At the same time, TRIP6 promoted NFB activation and cell migration 
[70]. Another protein recently proposed to regulate Fas signalling specifically in lymphoid 
cells is Toso (Fig. 6d) [138]. Toso is an immune-specific cell surface protein. Originally 
described as an inhibitor of Fas-mediated apoptosis through its ability to bind to FADD 
[139,140], Toso was recently shown to associate with FADD in a RIP1-dependent fashion, 
not only preventing apoptosis, but also promoting the activation of NFB and the ERK1/2 
MAPK signalling pathway [138].  
Together these studies suggest that the DISC and the signalling proteins recruited to 
the DISC play a major role in the outcome of Fas ligation, with the levels and/or activation of 
the proteins recruited determining the signalling cascade that predominates and thus playing a 
major role in determining the fate of the cell. 
 
Non-DISC-interacting proteins as determinants of cell fate: 
Recent studies have determined that the outcome of Fas ligation may also be mediated 
by non-DISC-interacting proteins such as mutated PI3K catalytic subunit α (PIK3CA) [141] 
and oncogenic K-Ras (Fig. 6e) [119]. In colon cancer cells, expression of mutated PI3K 
catalytic subunit α (PIK3CA) was shown to allow robust caspase-8 activation following Fas 
activation in the absence of apoptosis [141]. In these cells, mutant PIK3CA switched the Fas 
signal from apoptosis to NFB activation and cell invasion. Enhanced cell invasion required 
caspase-8-mediated cleavage of the protein kinase rho-associated, coiled-coil containing 
protein kinase 1(ROCK-1), leading to remodelling of the actin cytoskeleton and 
invasion[141]. Oncogenic K-Ras, in turn, not only prevents Fas-mediated apoptosis, but also 
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promotes Fas-mediated cell motility and invasion [119,142]. Oncogenic K-Ras was shown to 
prevent caspase-8 processing [142], with the K-Ras effector, Raf1, essential for the switch 
from apoptosis to cell invasion [119]. The ability of these oncogenic proteins to switch the 
signalling output of Fas from apoptosis to that promoting invasion is consistent with the fact 
that many tumours retain expression of Fas, albeit at a reduced level [143], suggesting that 
expression of Fas is advantageous to the tumour [38].    
 
Tissue Microenvironment in the regulation of Fas signalling: 
The presence of cytokines and growth factors in the microenvironment could 
potentially play an important role in the outcome of Fas ligation (Fig. 6f). For instance, short-
term cultured astrocytes express Fas but are resistant to Fas-mediated apoptosis and secrete 
IL-8 following Fas engagement. In the presence of interferon-gamma (IFN) however, 
resistant astrocytes become sensitive to Fas-mediated death [144]. Similarly, engagement of 
Fas, in combination with IFN, resulted in apoptosis of HT29 colon carcinoma cells, while 
Fas ligation alone resulted in IL-8 synthesis [145]. Exposure to growth factors such as 
epidermal growth factor (EGF) and hepatocyte growth factor (HGF) prior to Fas activation 
may not only confer resistance to Fas-mediated apoptosis, and instead promote Fas-induced 
cell proliferation through activation of the PI3K/Akt pathway [146]. Cytokines may also 
promote Fas-mediated apoptosis, with IL-2 shown to enhance the sensitivity of colon cancer 
cells in vitro to Fas-mediated apoptosis [147]. Finally, cytokines in the microenvironment can 
enhance Fas signalling, with IL-7 shown to synergize with Fas to induce proliferation of sub-
optimally activated T cells [148]. Thus, from a physiological standpoint, the response of cells 
to Fas ligation is likely to be influenced by the cellular microenvironment in vivo.  
 
Conclusions 
Studies of the Fas receptor have shed new light on the physiological function of this 
molecule, extending its function beyond that of the ‘prototypical’ death receptor to include 
proliferation, inflammation and invasion. The factors identified to date that determine the 
cellular response to Fas ligation are varied, ranging from the level of the receptor, to DISC-
interactions, to microenvironmental signals. Given that excessive or insufficient apoptosis 
underlie, among others, autoimmune and neoplastic diseases respectively, detailed 
characterization of the mechanisms that determine the outcome of Fas signalling may identify 
potential targets to allow the switching of this outcome, as appropriate. This knowledge may 
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be particularly important in the development of novel therapeutic targets for neoplastic 
disease as these non-apoptotic signals of Fas first became particularly evident in apoptosis-
resistant tumour cells.  
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Fig.1 Mitogenic signalling pathways implicated in Fas-induced proliferation. Following 
Fas stimulation, formation of the DISC occurs. Fas-mediated activation of the NFB 
transcription factor and the MAPK signalling pathways downstream of the DISC can promote 
cell proliferation. FasL can also induce ligand-dependent EGFR (epidermal growth factor 
receptor) activation and phosphorylation, which triggers mitogenic signalling through ERK. 
Neurite growth requires recruitment of ezrin to Fas and activation of the small GTPase Rac1. 
Dashed lines represent signalling pathways/intermediaries that not fully elucidated.   
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Fig.2 Fas-mediated suppression of T cell activation. In T cells, activation of acidic 
sphingomyelinase  (aSMase) following Fas ligation can increase the level of ceramide in the 
cells, which in turn inhibits Ca
2+
 release-activated Ca
2+
 channels (CRAC) in the plasma 
membrane. Impairment of CRAC opening prevents sustained Ca
2+
 influx, leading to 
suppressed NFAT activation and impaired T cell activation. Dashed lines represent signalling 
pathways/intermediaries that not fully elucidated.   
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Fig.3 Signalling pathways implicated in Fas-mediated migration.  Multiple signalling 
pathways have been shown to play a role in the induction of cell migration and invasion by 
Fas. Ligation of Fas stimulates platelet-derived growth factor receptor- β (PDGFR-β) tyrosine 
phosphorylation by an unknown mechanism, leading to phosphorylation of phospholipase C-
1 (PLC-1), with the subsequent release of cofilin from the cell membrane. Together with 
Fas-activated Rac, this leads to the formation of cell protrusions. Fas activation also results in 
the recruitment of the p85 subunit of PI3K and the tyrosine kinases Yes and Syk to Fas, 
activating Akt and NFB. Fas-induced NFB and ERK MAPK activation may also lead to 
cell migration in a TRAF2-mediated fashion. Association of TRIP6 with Fas following Fas 
activation can inhibit apoptosis, and promote NFB activation and cell migration. MMPs and 
uPA are among the genes most prominently upregulated in response to Fas ligation, and 
together facilitate migration and invasion. Dashed lines represent signalling 
pathways/intermediaries that not fully elucidated.   
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Fig.4 Signalling pathways involved in Fas-mediated inflammation. Activation of Fas 
may promote inflammation via activation of the p38, ERK and JNK MAPK signalling 
pathways and the NFB transcription factor downstream of the DISC. Interaction of MyD88 
directly with Fas may also activate the JNK and ERK MAPK signaling pathways, 
independently of FADD, and mediate Fas-induced inflammation. Alternatively, in the 
absence of Fas ligation, the Fas adaptor molecule, FADD may interact with MyD88 in the 
cytoplasm, potentially blocking/limiting MyD88 signalling. Dashed lines represent signalling 
pathways/intermediaries that not fully elucidated.   
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Fig.5 Reverse signalling through FasL. In addition to initiating signalling through Fas, 
membrane-bound FasL can also transmit a co-stimulatory signal in the reverse direction upon 
ligation of Fas, a process known as reverse or retrograde signaling. Binding of Src homology 
3 domain-containing proteins such as Fyn, Grb2, and PI3K to FasL leads to the subsequent 
activation of the MAPK ERK1/2 signaling pathway. Interaction of FasL with the hepatocyte 
growth factor receptor, Met, can also activate the Met-Stat3 signaling pathway. Dashed lines 
represent signalling pathways/intermediaries that not fully elucidated.   
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Fig.6 Multi-level regulation of the Fas signalling pathway. The outcome of Fas ligation 
is regulated at several points along the signalling pathway. (a) FasL may exist as either sFasL 
or mFasL, and they vary in their ability to induce apoptosis and/or non-apoptotic signalling. 
(b) At the receptor level, defective internalisation of the Fas signalling complex or the 
presence of mutations in one Fas allele may inhibit apoptosis and promote non-apoptotic 
signalling. (c) The balance between the ratio of cFLIP and pro-caspase-8 at the DISC may 
determine the outcome of Fas ligation. (d) Recruitment of proteins such as TRIP6 and Toso 
to the DISC can inhibit cell death, and promote the activation of non-apoptotic signalling 
pathways by Fas. (e) In addition to inhibiting apoptosis, oncogenic K-Ras and mutated PI3K 
catalytic subunit α (PIK3CA) promote Fas-mediated invasion through effects on receptor 
internalisation and the actin cytoskeleton. (f) Cell fate following Fas ligation was also shown 
to be regulated by growth factors and cytokines present in the cell microenvironment.  
 
